Amaris; London, UK.
Hum Vaccin Immunother. 2013 Nov;9(11):2285-95. doi: 10.4161/hv.25754. Epub 2013 Jul 23.
A critical review of cost-effectiveness analyses of HPV vaccination in males was conducted and nine studies were identified in different countries. Due to the heterogeneity among these studies in terms of modeling approach, vaccination strategies, health outcomes considered, assumptions and parameters, limited conclusions can be drawn with regard to the absolute cost-effectiveness. Nevertheless, key drivers were identified. More favorable cost-effectiveness appeared when all HPV-related diseases outcomes were considered, a suboptimal vaccine coverage among girls and/or lower vaccine prices were assumed. There was a general lack of transparency to fully describe the details of the methodological approach of modeling and calibration. Further research should be conducted to generate robust evidence-based data sets (HPV-related diseases epidemiology, costs and quality of life). The best modeling practice for HPV vaccination and how to better capture the true economic value of vaccination beyond cost-effectiveness in a broader policy context need to be investigated.
对 HPV 疫苗接种在男性中的成本效益分析进行了评论性综述，在不同国家中确定了 9 项研究。由于这些研究在建模方法、疫苗接种策略、考虑的健康结果、假设和参数方面存在异质性，因此对于绝对成本效益的结论是有限的。然而，已经确定了关键驱动因素。当考虑所有与 HPV 相关的疾病结果时，更有利的成本效益出现，假设女孩中的疫苗接种覆盖率不理想和/或疫苗价格较低。在充分描述建模和校准方法的详细信息方面普遍缺乏透明度。应开展进一步的研究，以生成基于证据的稳健数据集（HPV 相关疾病的流行病学、成本和生活质量）。需要研究 HPV 疫苗接种的最佳建模实践，以及如何在更广泛的政策背景下，除了成本效益之外，更好地捕捉疫苗接种的真实经济价值。
